MDxHealth SA (NASDAQ:MDXH) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of MDxHealth SA (NASDAQ:MDXH) have received an average rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.75.

MDXH has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th.

Institutional Trading of MDxHealth

A number of hedge funds have recently bought and sold shares of the business. Kennedy Capital Management LLC acquired a new stake in MDxHealth in the 3rd quarter valued at about $1,826,000. FreeGulliver LLC grew its stake in shares of MDxHealth by 25.7% in the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after buying an additional 65,000 shares during the period. Mink Brook Asset Management LLC grew its stake in shares of MDxHealth by 64.9% in the 4th quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock valued at $940,000 after buying an additional 103,686 shares during the period. Renaissance Technologies LLC grew its stake in shares of MDxHealth by 23.3% in the 4th quarter. Renaissance Technologies LLC now owns 250,100 shares of the company’s stock valued at $893,000 after buying an additional 47,300 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of MDxHealth by 96.0% in the 4th quarter. Russell Investments Group Ltd. now owns 194,097 shares of the company’s stock valued at $693,000 after buying an additional 95,054 shares during the period.

MDxHealth Trading Down 4.8%

MDXH stock opened at $2.20 on Friday. The company has a market cap of $108.90 million, a price-to-earnings ratio of -3.28 and a beta of 1.73. MDxHealth has a 12 month low of $1.55 and a 12 month high of $5.33. The firm has a 50-day moving average of $3.01 and a two-hundred day moving average of $3.56.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). The business had revenue of $29.55 million during the quarter, compared to analyst estimates of $26.05 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. As a group, equities analysts forecast that MDxHealth will post -1.15 earnings per share for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.